WO2012078288A3 - Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë - Google Patents

Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë Download PDF

Info

Publication number
WO2012078288A3
WO2012078288A3 PCT/US2011/059843 US2011059843W WO2012078288A3 WO 2012078288 A3 WO2012078288 A3 WO 2012078288A3 US 2011059843 W US2011059843 W US 2011059843W WO 2012078288 A3 WO2012078288 A3 WO 2012078288A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid leukemia
acute myeloid
methods
determining risk
dnmt3a
Prior art date
Application number
PCT/US2011/059843
Other languages
English (en)
Other versions
WO2012078288A2 (fr
Inventor
Timothy J. Ley
Richard K. Wilson.
Elaine K. Mardis
Li Ding
John K. Dipersio.
Original Assignee
Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University filed Critical Washington University
Publication of WO2012078288A2 publication Critical patent/WO2012078288A2/fr
Publication of WO2012078288A3 publication Critical patent/WO2012078288A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a pour objet des méthodes de détermination du risque d'évolution défavorable chez un sujet chez qui on a diagnostiqué une leucémie myéloïde aiguë ou un syndrome myélodysplasique. Les méthodes comprennent les étapes consistant à prévoir un échantillon comprenant des cellules de moelle osseuse et/ou du sang périphérique prélevé sur un sujet chez qui on a diagnostiqué une leucémie myéloïde aiguë ou un syndrome myélodysplasique, à séquencer au moins un exon de DNMT3A compris dans l'échantillon, et à identifier des mutations, s'il y en a, dans le gène DNMT3A. La présence d'une ou plusieurs mutations dans DNMT3A peut indiquer que le sujet présente un risque élevé d'évolution défavorable.
PCT/US2011/059843 2010-11-08 2011-11-08 Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë WO2012078288A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45656010P 2010-11-08 2010-11-08
US61/456,560 2010-11-08

Publications (2)

Publication Number Publication Date
WO2012078288A2 WO2012078288A2 (fr) 2012-06-14
WO2012078288A3 true WO2012078288A3 (fr) 2012-08-02

Family

ID=46207643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/059843 WO2012078288A2 (fr) 2010-11-08 2011-11-08 Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë

Country Status (1)

Country Link
WO (1) WO2012078288A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2997159B1 (fr) * 2013-05-13 2019-07-24 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Procédé de détermination de la prédisposition d'un individu humain à contracter une maladie myeloïde hematopoïetique maligne
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
BR112018007671B1 (pt) * 2015-10-15 2023-10-17 Les Laboratoires Servier Usos de um inibidor da idh1 e combinações
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
EA039805B1 (ru) * 2015-11-13 2022-03-15 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных опухолей
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN110564827A (zh) * 2019-09-19 2019-12-13 合肥艾迪康医学检验实验室有限公司 检测dnmt3a基因突变的引物、试剂盒和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234997A1 (en) * 1998-06-25 2004-11-25 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
US20070198198A1 (en) * 2003-04-29 2007-08-23 Wyeth Methods and apparatuses for diagnosing AML and MDS
US20090317801A1 (en) * 2005-08-02 2009-12-24 Sequenom, Inc. Methods and compositions for disease prognosis based on nucleic acid methylation
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234997A1 (en) * 1998-06-25 2004-11-25 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20070198198A1 (en) * 2003-04-29 2007-08-23 Wyeth Methods and apparatuses for diagnosing AML and MDS
US20090317801A1 (en) * 2005-08-02 2009-12-24 Sequenom, Inc. Methods and compositions for disease prognosis based on nucleic acid methylation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BULLINGER ET AL.: "Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia.", N ENGL J MED., vol. 350, no. 16, 2004, pages 1605 - 1616, XP009059431, DOI: doi:10.1056/NEJMoa031046 *
CHEN ET AL.: "A Novel Dnmt3a Isoform Produced from an Alternative Promoter Localizes to Euchromatin and Its Expression Correlates with Active de Novo Methylation.", J BIOL CHEM., vol. 277, no. 41, 2002, pages 38746 - 38754 *
FRIED ET AL.: "Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy- related and secondary acute myeloid leukemia.", HAEMATOLOGICA., vol. 97, no. 2, 2012, pages 246 - 250 *
LEY ET AL.: "DNA sequencing of a cytogenetically normal acute myeloid leukemia genome.", NATURE., vol. 456, no. 7218, 2008, pages 66 - 72, XP055052871, DOI: doi:10.1038/nature07485 *
LEY ET AL.: "DNMT3A Mutations in Acute Myeloid Leukemia.", N ENGL J MED., vol. 363, no. 25, 16 December 2010 (2010-12-16), pages 2424 - 2433 *
LIN ET AL.: "Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.", PLOS ONE., vol. 6, no. 10, 2011, pages E26906 *
RIBEIRO ET AL.: "Mutant DNMT3A: a new marker of poor prognosis in acute myeloid leukemia.", BLOOD., 5 April 2012 (2012-04-05), Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/22490330> [retrieved on 20120507] *
ROBERTSON ET AL.: "The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors", NUCLEIC ACIDS RES., vol. 27, no. 11, 1999, pages 2291 - 2298, XP002123986, DOI: doi:10.1093/nar/27.11.2291 *
SILVERMAN: "The Role of Methyltransferase Inhibitors in the Management of the Myelodysplastic Syndromes.", CANCER CONTROL., vol. 11, no. 6, 2004, pages 11 - 15 *
YAMASHITA ET AL.: "Array-based genomic resequencing of human leukemia.", ONCOGENE., vol. 29, no. 25, June 2010 (2010-06-01), pages 3723 - 3731 *

Also Published As

Publication number Publication date
WO2012078288A2 (fr) 2012-06-14

Similar Documents

Publication Publication Date Title
WO2012078288A3 (fr) Méthodes de détermination du risque d&#39;évolutions défavorables dans la leucémie myéloïde aiguë
EP3236262A3 (fr) Essai de diagnostic fonctionnel de substitut pour le cancer
WO2012103031A3 (fr) Détection d&#39;anomalies génétiques
EP2569453A4 (fr) Méthodes d&#39;isolement de l&#39;acide nucléique
NZ621733A (en) Lung cancer biomarkers and uses thereof
WO2015100459A3 (fr) Profils de biomarqueur pour prédire les résultats d&#39;une thérapie cancéreuse utilisant des inhibiteurs d&#39;erbb3 et/ou des chimiothérapies
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
EP3572529A3 (fr) Diagnostic du cancer colorectal basé sur la méthylation de gènes
WO2011087709A3 (fr) Translocations d&#39;eml4-alk dans le cancer pulmonaire
WO2014078468A3 (fr) Biomarqueurs destinés à prédire une réponse clinique de patients cancéreux suite à un traitement avec un agent immunothérapeutique
WO2010028373A3 (fr) Procédés pour diagnostiquer le cancer et déterminer la survie globale et la survie sans maladie des patients atteints du cancer
WO2016145308A3 (fr) Marqueurs d&#39;arnm à base de sang total pour prédire un cancer de la prostate, et leurs procédés de détection
WO2009082744A3 (fr) Pronostic et traitement véhiculé par interférence du cancer du sein
WO2015095862A3 (fr) Biomarqueurs de micro-arn pour le cancer de l&#39;ovaire
WO2012040500A3 (fr) Dosage direct dans le sang destiné à détecter un microarn circulant chez des patients atteints de cancer
WO2015085164A3 (fr) Pronostic du mélanome uvéal
WO2013077814A3 (fr) Prédiction de la susceptibilité au lymphome nk/t et diagnostic et traitement du lymphome nk/t
WO2014198670A3 (fr) Procédés de visualisation et d&#39;analyse de données biologiques à contenu élevé
WO2012003493A3 (fr) Mutation génétique de la protéine kinase ck2, amplifications et polymorphismes dans les cancers humains, et procédés d&#39;utilisation
WO2010079339A3 (fr) Facteurs
BR112012026314A2 (pt) biomarcador para função renal em pacientes com diabetes do tipo 2
WO2017156154A9 (fr) Compositions pour caractériser le développement d&#39;un adénocarcinome oesophagien chez des patients et procédés pour leur utilisation
WO2012158880A3 (fr) Cancers anaplasiques de la thyroïde comportant de nouvelles mutations oncogènes du gène alk
UA104686U (uk) Спосіб прогнозування зрощення перелому
UA95605U (uk) Спосіб прогнозування зрощення перелому

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846822

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11846822

Country of ref document: EP

Kind code of ref document: A2